MCID: OVR012
MIFTS: 46

Ovarian Serous Cystadenocarcinoma malady

Summaries for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
32MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MalaCards: Ovarian Serous Cystadenocarcinoma is related to cystadenocarcinoma and ovarian cancer. An important gene associated with Ovarian Serous Cystadenocarcinoma is ESR2 (estrogen receptor 2 (ER beta)), and among its related pathways are IL-3 Signaling Pathway and TNF Signaling. The compounds resveratrol and idoxifene have been mentioned in the context of this disorder. Affiliated tissues include ovary, colon and breast, and related mouse phenotypes are renal/urinary system and hearing/vestibular/ear.

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
8Disease Ontology, 10DISEASES, 44Novoseek, 60UMLS, 39NCIt
See all sources

Aliases & Descriptions:

ovarian serous cystadenocarcinoma 8 10 44 60


External Ids:

Disease Ontology8 DOID:5746
NCIt39 C7978

Related Diseases for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 123)
idRelated DiseaseScoreTop Affiliating Genes
1cystadenocarcinoma31.2MUC16
2ovarian cancer30.5MUC16, BAX, VEGFA, AKT1, FAS, CYP19A1
3leukemia30.3FAS, AKT1, BAX, BIRC5, ESR2, BCL2
4endometriosis30.3VEGFA, MUC16, CYP19A1, PGR, ESR1, ESR2
5serous cystadenocarcinoma10.8
6ovarian cystadenocarcinoma10.8
7ovarian endometriosis10.2
8peritonitis10.0MUC16
9malignant mesothelioma10.0MUC16
10anaplastic large cell lymphoma10.0MUC16
11thyroid cancer10.0AKT1
12arthritis10.0ESR2
13rhabdomyosarcoma10.0AKT1
14neuroblastoma10.0AKT1
15osteoarthritis10.0ESR2
16pituitary adenoma10.0ESR2
17tuberous sclerosis10.0AKT1
18deficiency anemia10.0MUC16
19cervical intraepithelial neoplasia10.0BIRC5
20multiple myeloma10.0AKT1
21obesity10.0AKT1
22sertoli-leydig cell tumor10.0PGR
23thymoma10.0AKT1
24hepatoblastoma10.0BIRC5
25medulloblastoma10.0AKT1
26acute leukemia10.0BIRC5
27dementia10.0ESR2
28brain cancer10.0BAX
29meigs syndrome10.0MUC16
30parkinson's disease10.0BAX
31monocytic leukemia10.0FAS
32hepatitis c10.0FAS
33leydig cell tumor10.0CYP19A1
34azoospermia10.0ESR2, USP2
35leiomyosarcoma10.0MUC16, PGR
36adenofibroma10.0MUC16
37ataxia telangiectasia10.0BAX
38fibromatosis10.0PGR
39cerebral meningioma10.0PGR
40prion disease10.0AKT1
41teratoma10.0NANOG
42atherosclerosis10.0ESR2, AKT1
43oral cancer10.0BIRC5, BAX
44graves' disease10.0ESR2, FAS
45polycystic ovary syndrome10.0ESR2, CYP19A1
46insulin resistance10.0ESR2, AKT1
47gastrointestinal system disease10.0BAX
48myelodysplastic syndromes10.0BIRC5, FAS
49seminoma10.0NANOG, ESR2
50ductal carcinoma in situ10.0ESR1, PGR

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to ovarian serous cystadenocarcinoma

Clinical Features for Ovarian Serous Cystadenocarcinoma

About this section

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
5CenterWatch, 41NIH Clinical Center, 6ClinicalTrials, 60UMLS, 40NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Ovarian Serous Cystadenocarcinoma

Drug clinical trials:

Search ClinicalTrials for Ovarian Serous Cystadenocarcinoma

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Search CenterWatch for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

About this section

Anatomical Context for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
32MalaCards
See all sources

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

32
Ovary, Colon, Breast, Testis

Animal Models for Ovarian Serous Cystadenocarcinoma or affiliated genes

About this section
Sources:
36MGI
See all sources

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

36 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000536710.2ESR2
2MP:000537710.2ESR2, FAS
3MP:00053759.9CYP19A1
4MP:00107719.7FAS, AKT1, VEGFA, BCL2
5MP:00030129.3PGR, NANOG, USP2
6MP:00053859.2FAS, AKT1, CYP19A1, PGR, ESR1, ESR2
7MP:00053799.2FAS, USP2, AKT1, BAX, ESR2, BCL2
8MP:00053769.2USP14, AKT1, PGR, ESR1
9MP:00020069.0FAS, AKT1, VEGFA, PGR, ESR1, ESR2
10MP:00053699.0USP14, BAX, CYP19A1, ESR1, ESR2
11MP:00053709.0FAS, AKT1, VEGFA, CYP19A1, ESR1, ESR2
12MP:00053888.9FAS, AKT1, VEGFA, BAX, ESR1, ESR2
13MP:00036318.5FAS, USP14, BAX, CYP19A1, ESR2, BCL2
14MP:00053978.4FAS, AKT1, VEGFA, BAX, CYP19A1, PGR
15MP:00053898.3BCL2, FAS, USP14, USP2, AKT1, VEGFA
16MP:00053878.3FAS, AKT1, VEGFA, BAX, CYP19A1, PGR
17MP:00053908.3FAS, USP14, AKT1, VEGFA, BAX, CYP19A1
18MP:00053867.6FAS, USP14, USP2, AKT1, VEGFA, BAX
19MP:00107687.2FAS, USP14, AKT1, VEGFA, BAX, NANOG
20MP:00053847.0FAS, USP14, AKT1, VEGFA, BAX, CYP19A1

Publications for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
50PubMed
See all sources

Articles related to Ovarian Serous Cystadenocarcinoma:

(show all 29)
idTitleAuthorsYear
1
Ovarian serous cystadenocarcinoma metastasising to the breast. (23445161)
2013
2
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. (21266826)
2010
3
Serous ovarian cystadenocarcinoma incidentally discovered in a 29-year-old patient: case report. (21077487)
2010
4
Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic treatment for a presumed benign ovarian cyst. (19317271)
2009
5
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
6
Plasma cell leukemia with ovarian serous cystadenocarcinoma. (17883177)
2007
7
Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. (17553343)
2007
8
ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. (17160949)
2006
9
Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. (16793610)
2006
10
Mean nuclear volume in ovarian papillary serous cystadenocarcinoma. (15032078)
2004
11
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
12
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. (11516810)
2001
13
Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma. (12574850)
2001
14
Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: a possible association with calcification of psammoma bodies. (10886734)
2000
15
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. (10968352)
2000
16
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
17
Ovarian serous papillary cystadenocarcinoma stage IIIC in a 19-year-old. (9038277)
1997
18
Serous cystadenocarcinoma and ovarian teratoma during pregnancy. (8737305)
1996
19
Ovarian-type papillary serous cystadenocarcinoma of the testis. (8653294)
1996
20
Colonic carcinoma metastasis to ovary having serous cystadenocarcinoma -- an unusual case of double ovarian malignancy. (8932579)
1995
21
Primary retroperitoneal serous cystadenocarcinoma of 'ovarian-type': US and CT findings. (8223678)
1993
22
Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. (1427402)
1992
23
Successful pregnancy after conservative surgery for ovarian papillary serous cystadenocarcinoma of low malignant potential. (1785199)
1991
24
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
25
Osseous metaplasia in ovarian papillary serous cystadenocarcinoma. (2121630)
1990
26
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). (3165255)
1988
27
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. (3598277)
1987
28
Cytogenetics of a cell line derived from an ovarian papillary serous cystadenocarcinoma. (6744227)
1984
29
Ultrastructure of ovarian tumors. I. Papillary serous cystadenocarcinoma. (4910128)
1970

Genetic Variations for Ovarian Serous Cystadenocarcinoma

About this section

Expression for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Sources:
37NCBI BioSystems Database, 55SinoBiological, 52R&D Systems, 53Reactome, 49PharmGKB, 51QIAGEN, 12EMD Millipore, 29KEGG, 4Cell Signaling Technology
See all sources

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 32)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.3BIRC5
2
Hide members
10.3AKT1
39.8CYP19A1, PGR, ESR2
49.8ESR2, ESR1, AKT1
59.8AKT1, ESR1, ESR2
6
Hide members
9.8ESR2, ESR1, PGR
79.8BCL2, BIRC5, AKT1
8
Hide members
9.8ESR2, ESR1, CYP19A1
9
Hide members
9.8BCL2, BAX, AKT1
10
Hide members
9.8BCL2, BAX, AKT1
119.8BCL2, BAX, AKT1
129.8BCL2, BAX, AKT1
139.7FAS, BAX, BCL2
149.7AKT1, ESR1, BCL2
15
Hide members
9.5AKT1, BAX, BIRC5, BCL2
169.5FAS, BAX, BIRC5, BCL2
17
Apoptosis and survival Apoptotic TNF-family pathways
Hide members
9.5BCL2, BIRC5, BAX, FAS
18
Hide members
9.5BCL2, BAX, AKT1, FAS
19
Apoptosis and survival Caspase cascade
Hide members
9.5FAS, AKT1, BAX, BCL2
20
Development Endothelin-1/EDNRA signaling
Hide members
9.5AKT1, VEGFA, ESR1, ESR2
21
Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR2
Hide members
9.5BAX, ESR1, ESR2, BCL2
22
Hide members
9.3FAS, AKT1, BAX, BIRC5, BCL2
23
Hide members
9.3BCL2, BIRC5, BAX, AKT1, FAS
24
Development Prolactin receptor signaling
Hide members
9.3AKT1, BAX, ESR1, ESR2, BCL2
25
Hide members
9.2AKT1, BAX, NANOG, BCL2
269.0FAS, AKT1, VEGFA, BAX, BIRC5, BCL2
27
Hide members
8.9FAS, AKT1, VEGFA, BAX, ESR1, BCL2
288.9ESR1, NANOG, VEGFA, AKT1, FAS
298.9AKT1, VEGFA, BAX, CYP19A1, ESR1, BCL2
308.7BCL2, FAS, AKT1, VEGFA, BAX, ESR1
318.7AKT1, AMY1A, AMY1B, AMY1C
32
Hide members
8.6CYP19A1, AMY1A, AMY1B, AMY1C

Compounds for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Sources:
44Novoseek, 59Tocris Bioscience, 11DrugBank, 24HMDB, 49PharmGKB, 28IUPHAR, 2BitterDB
See all sources

Compounds related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 199)
idCompoundScoreTop Affiliating Genes
1resveratrol44 59 11 2413.7PGR
2idoxifene4410.1PGR, ESR1, CYP19A1
3ponicidin4410.0BCL2, BIRC5, BAX
4estradiol benzoate449.9ESR1, PGR, CYP19A1, ESR2
5nandrolone44 2410.9CYP19A1, PGR, ESR1, ESR2
6leuprolide acetate449.9CYP19A1, PGR, ESR1, ESR2
7tanshinone iia449.9BAX, FAS, BCL2
8exemestane49 44 59 1112.9ESR1, PGR, CYP19A1, ESR2
9bisphenol a449.9ESR1, PGR, CYP19A1, ESR2
10lapatinib44 49 1111.9PGR, BIRC5, CYP19A1, ESR1
11clomiphene citrate449.9ESR1, ESR2, PGR, CYP19A1
123,3-diindolylmethane449.8VEGFA, BIRC5, ESR1, BAX
13fulvestrant44 49 28 1112.8CYP19A1, ESR2, ESR1, PGR
14hoechst 33342449.8BCL2, BIRC5, FAS, BAX
15letrozole44 49 59 1112.8CYP19A1, ESR2, ESR1, PGR
16levonorgestrel44 59 28 1112.7ESR1, CYP19A1, PGR, ESR2
175fluorouracil449.7FAS, BAX, PGR, BIRC5, BCL2
18toremifene44 1110.7FAS, CYP19A1, PGR, ESR1, ESR2
19noxa449.7BAX, BCL2, BIRC5, FAS
204-hydroxytamoxifen449.7CYP19A1, AKT1, ESR1, PGR, ESR2
21steroidal449.5ESR1, CYP19A1, ESR2, PGR
22progestin449.5CYP19A1, ESR1, PGR, VEGFA, ESR2
23adriamycin449.5BCL2, BIRC5, BAX, AKT1, FAS, PGR
24indole-3-carbinol449.5BAX, AKT1, CYP19A1, BIRC5, ESR1, BCL2
25gefitinib44 49 1111.4AKT1, VEGFA, ESR2, CYP19A1, ESR1, BIRC5
262-chlorodeoxyadenosine449.4BIRC5, BAX, FAS, BCL2
27trastuzumab44 49 1111.4VEGFA, ESR1, BIRC5, PGR, CYP19A1, FAS
28thymidylate449.4FAS, BCL2, VEGFA, BAX, BIRC5, ESR2
29celecoxib44 59 28 49 11 2414.4VEGFA, BCL2, CYP19A1, BAX, AKT1, BIRC5
30gemcitabine44 49 1111.4BCL2, BIRC5, CYP19A1, BAX, VEGFA, AKT1
31taxane449.4VEGFA, CYP19A1, PGR, BIRC5, BCL2, ESR1
32etoposide44 49 59 1112.4AKT1, BAX, FAS, ESR2, BCL2
33dexamethasone44 49 28 1112.3AKT1, VEGFA, MUC16, BIRC5, BCL2, FAS
34mifepristone44 59 28 1112.2VEGFA, BAX, CYP19A1, PGR, BIRC5, ESR2
35arsenite44 2410.2AKT1, BCL2, FAS, VEGFA, BAX, PGR
36mg 13244 5910.2BAX, FAS, VEGFA, AKT1, BIRC5, ESR1
37docetaxel44 49 59 1112.1BAX, PGR, BIRC5, ESR1, BCL2, CYP19A1
38ly294002449.1VEGFA, FAS, AKT1, BAX, BIRC5, ESR1
39sb 20358044 5910.0BAX, BCL2, BIRC5, FAS, VEGFA, AKT1
40actinomycin d448.9ESR1, BIRC5, BAX, VEGFA, AKT1, FAS
41testosterone44 59 11 2411.8ESR2, ESR1, BIRC5, FAS, AKT1, MUC16
42cisplatin44 49 59 1111.8BCL2, BIRC5, FAS, MUC16, BAX, AKT1
43n acetylcysteine448.7BAX, BCL2, AKT1, FAS, VEGFA, BIRC5
44retinoic acid44 249.6BIRC5, AKT1, BAX, CYP19A1, PGR, ESR2
45tamoxifen44 49 28 1111.5BCL2, ESR2, FAS, AKT1, VEGFA, CYP19A1
46genistein44 28 59 2 11 2413.5ESR2, BCL2, FAS, AKT1, VEGFA, BAX
47paraffin448.4AKT1, FAS, BAX, MUC16, PGR, VEGFA
48vegf448.4FAS, BCL2, ESR2, ESR1, VEGFA, BIRC5
49paclitaxel44 49 1110.4MUC16, FAS, BIRC5, BCL2, AKT1, BAX
50doxorubicin44 49 1110.2BCL2, VEGFA, PGR, ESR1, FAS, CYP19A1

GO Terms for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Sources:
16Gene Ontology
See all sources

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:0469309.9BCL2, BAX
2mitochondrial outer membraneGO:0057419.7BCL2, PGR, BAX
3nucleoplasmGO:0056548.4AKT1, NANOG, PGR, ZNF217, ESR1, ESR2

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 21)
idNameGO IDScoreTop Affiliating Genes
1activation-induced cell death of T cellsGO:00692410.3FAS, AKT1
2regulation of nitrogen utilizationGO:00680810.3BCL2, BAX
3renal system processGO:00301410.2BCL2, FAS
4transformed cell apoptotic processGO:00692710.2FAS, BAX
5regulation of protein heterodimerization activityGO:04349710.2BAX, BCL2
6regulation of protein homodimerization activityGO:04349610.2BAX, BCL2
7vagina developmentGO:06006810.1ESR2, ESR1, BAX
8uterus developmentGO:06006510.1ESR1, ESR2
9neuron apoptotic processGO:05140210.0BCL2, BAX, FAS
10intrinsic apoptotic signaling pathwayGO:09719310.0BCL2, BAX, AKT1
11negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:04315410.0BIRC5, VEGFA, AKT1
12positive regulation of peptidyl-serine phosphorylationGO:03313810.0AKT1, VEGFA, BCL2
13positive regulation of sequence-specific DNA binding transcription factor activityGO:0510919.9ESR2, ESR1, AKT1
14response to toxic substanceGO:0096369.9BCL2, BAX, FAS
15response to acidGO:0011019.9BCL2, BAX
16ovarian follicle developmentGO:0015419.8BCL2, ESR2, BAX, VEGFA
17positive regulation of nitric-oxide synthase activityGO:0510009.7AKT1, ESR1
18positive regulation of mitotic cell cycleGO:0459319.7USP2, NANOG, BIRC5
19positive regulation of apoptotic processGO:0430659.6ESR2, BAX, AKT1, FAS
20negative regulation of apoptotic processGO:0430669.4FAS, AKT1, VEGFA, BIRC5, BCL2
21apoptotic processGO:0069159.3BCL2, BIRC5, BAX, AKT1, FAS

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:03405610.1ESR1, ESR2
2BH3 domain bindingGO:05143410.1BAX, BCL2
3estrogen receptor activityGO:03028410.0ESR2, ESR1
4core promoter sequence-specific DNA bindingGO:00104610.0ESR2, ESR1
5steroid bindingGO:00549610.0ESR2, ESR1, PGR
6nitric-oxide synthase regulator activityGO:0302359.9ESR1, AKT1
7steroid hormone receptor activityGO:0037079.9PGR, ESR1, ESR2
8channel activityGO:0152679.7BCL2, BAX
9enzyme bindingGO:0198999.6AKT1, PGR, BIRC5, ESR1, ESR2
10identical protein bindingGO:0428028.6BCL2, FAS, USP2, AKT1, VEGFA, BAX
11protein bindingGO:0055155.7AKT1, USP2, USP14, FAS, UBE4A, AMY1C

Products for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Ovarian Serous Cystadenocarcinoma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
50PubMed
51QIAGEN
57SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet